This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Infectious disease

Staphylococcus

CC chemokine receptor 5 (CCR5; CD195)

Cell culture and mouse studies suggest inhibiting CCR5 could help treat Staphylococcus aureus infections. In vitro, S. aureus leukotoxin killed CCR5-expressing cell lines. The effect was blocked with multiple small molecule CCR5 antagonists. In a model of S. aureus systemic infection, Ccr5 knockout mice had lower bacterial load and greater survival than wild-type mice. Next steps include developing animal models that can monitor the efficacy of CCR5 antagonists.
Pfizer Inc. markets the CCR5 antagonist Selzentry maraviroc to treat HIV/AIDS.

SciBX 6(1); doi:10.1038/scibx.2013.15
Published online Jan. 10, 2013

Patent application filed; licensing status undisclosed

Alonzo, F. III et al. Nature; published online Dec. 12, 2012;
doi:10.1038/nature11724
Contact: Victor J. Torres, New York University School of Medicine, New York, N.Y.
e-mail:
victor.torres@nyumc.org